Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALENDULA
2024-516028-33-01Phase 3Completed
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cabotegravir and lenacapavir in human immunodeficiency virus infection (HIV), sponsored by Institut de Médecine et d'Epidémiologie Appliquée. Primary endpoint: Virological failure at week 48. Started Sep 2024; status: completed.
02
Drugs
cabotegravirlenacapavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-516028-33-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516028-33-01.